Market Place
Sourcing Support
All News #Library
Invagen Pharms’ Generics Rivaroxaban Receives Approval in US
20 Feb 2026 //
FDA
InvaGen`s Generics Rivaroxaban Receives Approval in US
14 May 2025 //
FDA
Invagen Pharms`s Generics Linagliptin Receives Approval in US
03 Sep 2024 //
FDA
InvaGen`s Generic Vilazodone Hydrochloride Receives Approval in the U.S.
06 Dec 2022 //
FDA
Ascent Pharms Inc`s Generic Gabapentin Receives Approval in the US
01 Oct 2021 //
FDA
Ascent Pharms`s Generic Topiramate Receives Approval in the US
26 Aug 2021 //
FDA
Invagen Pharms` Generic Penicillamine Receives Approval in US
19 Aug 2021 //
FDA
InvaGen `s Generic Vilazodone Hydrochloride Receives Approval in US
10 Apr 2021 //
FDA
Ascent Pharms`s Generic Venlafaxine Hydrochloride Receives Approval In US
26 Oct 2020 //
FDA
InvaGen Pharmaceuticals`s Generic Vigabatrin Receives Approval in US
03 Dec 2019 //
FDA
Invagen Pharms Generic Pregabalin Receives Approval In US
23 Jul 2019 //
FDA
Ascent Pharms Generic Omega-3-acid Ethyl Esters Receives Approval In US
01 Mar 2019 //
FDA
Invagen Pharm`s Generic Lurasidone Hydrochloride Receives Approval in US
03 Jan 2019 //
FDA
Invagen Pharm’s Generics Sevelamer Carbonate Receives Approval In US
30 Oct 2017 //
FDA
Invagen Pharm’s Generic Bupropion Hydrochloride Receives Approval In US
21 Sep 2017 //
FDA
Invagen Pharms Generic Clindamycin Palmitate HCL Receives Approval In US
08 May 2017 //
FDA
Invagen Pharms Generic Fenofibrate Receives Approval In US
28 Mar 2017 //
FDA
Invagen`s Generic Atorvastatin Calcium Receives Approval In US
09 Jan 2017 //
FDA
Invagen`s Generic Lurasidone Hydrochloride Receives Tentative Approval In US
02 Dec 2016 //
FDA
Ascent`s Generic Dutasteride Received Approval In US
22 Oct 2016 //
FDA
Invagen Pharms Generic Amlodipine Besylate; Valsartan Approved In US
16 Sep 2016 //
FDA
Invagen Pharms ANDA Trospium Chloride Receives FDA Nod
24 Aug 2016 //
FDA
Invagen Pharm`s Generic Olanzapine approved in US for Schizophrenia
16 Mar 2016 //
FDA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.